Kimball Solutions’ second quarter saw headline declines in revenue and earnings per share. Management attributed the quarter’s performance to strong execution in the Medical vertical, which continued to grow and offset softness in Automotive and Industrial. CEO Richard Phillips specifically pointed to “broad-based improvement” in medical device demand and highlighted the company’s ability to generate strong operating cash flow, which helped reduce debt to its lowest level in over four years. The company also benefited from geographical diversification, with sales more evenly split between North America, Asia, and Europe compared to previous periods.
Is now the time to buy KE? Find out in our full research report (it’s free for active Edge members).
Kimball Solutions (KE) Q2 CY2026 Highlights:
- Revenue: $371.6 million vs analyst estimates of $373.4 million (2.3% year-on-year decline, in line)
- Adjusted EPS: -$0.01 vs analyst estimates of $0.39 (significant miss)
- Operating Margin: 4%, down from 5.3% in the same quarter last year
- Market Capitalization: $591.8 million
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Kimball Solutions’s Q2 Earnings Call
- Brett Fishbin (KeyBanc Capital Markets) asked about the drivers of Medical segment growth in Asia and Europe, and whether North America’s softness was structural or just a tough comparison. CEO Richard Phillips and CFO Jana Croom explained that growth was broad-based and North America’s dip was due to last year’s one-time inventory build.
- Brett Fishbin (KeyBanc Capital Markets) followed up on the expected contributors to Medical growth in the coming year, specifically regarding the Indianapolis facility’s ramp. Phillips indicated the impact from Indianapolis will be gradual, with most growth coming from existing categories and synergy with Helvoet.
- Michael Crawford (B. Riley Securities) inquired about EBITDA margin details and the expected financial drag from ramping up the new Indianapolis facility. Croom clarified the drag would be $6.5–7 million, with gradual improvement as the facility ramps.
- Derek Soderberg (Cantor Fitzgerald) probed the outlook for Automotive, asking when the segment might return to growth. Phillips highlighted stabilization, with European and Chinese programs performing well, but noted ongoing EV demand weakness in North America.
- Maxwell Michaelis (Lake Street Capital Markets) questioned the sustainability of gross margins and whether Medical growth would support margins above 8%. Croom confirmed that a gross margin of approximately 8.5% would be needed to achieve the guided operating margin.
Catalysts in Upcoming Quarters
Looking forward, our analysts will monitor (1) the pace and scale of Medical segment growth, particularly the integration of Helvoet and early production at the Indianapolis facility; (2) stabilization and potential recovery in Automotive sales, especially in Europe and China; and (3) changes to working capital efficiency as inventory and supply chain dynamics evolve. Effective execution on synergy capture and margin management will be key to tracking Kimball Solutions’ progress.
Kimball Solutions currently trades at $24.58, down from $25.19 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.